WIL Research Partners with Three S Japan
News May 24, 2013
WIL Research is partnering with Three S Japan, a company that provides support services in these industries, to represent its full portfolio of global safety assessment services in Japan.
WIL Research offers a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.
They chose the Japan-based company to represent these services on the basis of its extensive network of clients, leadership experience with both pharmaceutical and chemical industry safety assessment, and its commitment to providing tailored, local client service.
“Three S Japan has a strong reputation serving the country’s pharmaceutical industry with high quality regulatory services underpinned by exceptional client focus,” said David Spaight, Chairman and CEO of WIL Research.
Spaight continued, “Through this partnership, clients will benefit from direct access to staff that can harness the full portfolio of WIL Research’s global services.”
CEO and President of Three S Japan, Koichi Hagita said, “WIL Research’s excellent reputation and our long-term client relationships and regulatory experience in the Japanese market will boost both our companies’ potential for growth.”
Three S Japan has operational centers in Tokyo and Osaka for pharmaceutical regulatory registration services.
The company provides toxicological support from pre-clinical to clinical development, and is experienced in the preparation, translation, and quality control checks of submission documents for New Drug Applications and Investigational New Drug applications.
Three S Japan also offers personalized consulting tailored to clients’ needs.
WIL Research was recently one of the winners of the CRO Leadership Award for Quality, awarded annually to leaders in quality, productivity, regulatory, accessibility, and reliability.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019